Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.
Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback